SequelSEC

IO Biotech, Inc. IOBTQ

Pharmaceutical Preparations · CIK 0001865494 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2024-12-31
Operating income
-$95.18M
Fiscal year ended 2024-12-31
Free cash flow
-$82.39M
Fiscal year ended 2024-12-31

IO Biotech, Inc. (IOBTQ) reported net income of -$95.50M for the fiscal year ended 2024-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from IO Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

IO Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$95.18M-$91.44M-$71.42M-$41.23M-$10.14M
Net income-$95.50M-$86.08M-$71.46M-$67.88M-$12.04M
Research & development$71.48M$67.83M$46.99M$30.15M$8.46M
Weighted-average diluted sharesshares 65.88Mshares 43.54Mshares 28.82Mshares 4.34MUnavailable
Pretax income-$94.05M-$85.23M-$70.18M-$67.81M-$12.04M
Income tax expense$1.44M$852.00K$1.27M$68.00KUnavailable
Diluted EPS$-1.45$-1.98$-2.48$-17.30Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$23.69M$23.61M$24.44M$11.08M$1.68M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

IO Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$60.03M$143.19M$142.59M$211.53M$3.40M
Total assets$67.70M$150.72M$151.80M$222.29M$5.65M
Current assets$64.95M$147.26M$148.22M$221.74M$5.64M
Total liabilities$20.68M$17.56M$12.95M$10.36M$3.05M
Current liabilities$19.49M$15.72M$10.68M$10.30M$3.05M
Total equity incl. NCI$47.02M$133.16M$138.85M$211.92M-$35.30M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0UnavailableUnavailableUnavailableUnavailable
Accounts payable$4.66M$3.88M$4.00M$3.93M$522.00K

Cash flow

IO Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$82.35M-$71.74M-$59.73M-$40.65M-$9.96M
Capital expenditures$44.00K$323.00K$690.00K$153.00KUnavailable
Investing cash flow-$44.00K-$323.00K-$690.00K-$153.00KUnavailable
Financing cash flowUnavailable$71.86MUnavailable$252.95M$5.10M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$6.53M$8.06M$7.04M$1.79M$64.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$300.00K$200.00K$100.00K$0Unavailable

Derived

IO Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$82.39M-$72.06M-$60.42M-$40.80MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio3.33x9.37x13.88x21.52x1.85x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.00xUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IOBTQ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing
10-K · Filed 2025-03-31View SEC filing
10-Q · Filed 2024-11-12View SEC filing
10-Q · Filed 2024-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 37906000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.